FREM2 and breast carcinoma: Mezencev et al. reported an increased risk of glioma in young breast cancer patients and predicted a genetic contribution underlying the development of glioma in breast cancer patients below 45 years of age, which could be explained by the amplification of FREM2 and LINC02865 in young patients of our cohort (Mezencev, 2018).